From Autologous Transplant to Maintenance Therapy in Multiple Myeloma

By The Fellow on Call - Last Updated: August 1, 2023

Why do we use lenalidomide maintenance therapy post-stem cell transplant? In part eight of the Myeloma Series, The Fellow on Call discuss this question and others, including the following:

What is the maintenance strategy for high-risk patients?
What is the rationale for adding a proteasome inhibitor for high-risk patients?
What data shows efficacy of doublet maintenance therapy for high-risk patients

They also do a deep dive into the FORTE trial and discuss the role of daratumumab in the maintenance setting.

How to Approach Relapsed DLBCL After CAR-T Therapy

What to Know About Relapsed Disease Treatment After 12 Months in DLBCL

How to Approach Patients with Primary Refractory DLBCL

How Is Cellular Therapy Changing Care for Hematologic Malignancies?

How Has Treatment for Advanced DLBCL Evolved?

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center

Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center

Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer

From Autologous Transplant to Maintenance Therapy in Multiple Myeloma

Related